

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 July 2025 (17.07.2025)



(10) International Publication Number
WO 2025/151796 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) C12N 15/113 (2010.01)
A61P 25/02 (2006.01) A61K 48/00 (2006.01)
C07K 16/28 (2006.01)

777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MOLLER-TANK, Sven**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(21) International Application Number:

PCT/US2025/011206

(74) Agent: **WU, Rita**; 566 S. McCaslin Blvd., Unit 270743, Superior, Colorado 80027 (US).

(22) International Filing Date:

10 January 2025 (10.01.2025)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/619,765 11 January 2024 (11.01.2024) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **ALESSANDRI-HABER, Nicole M.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BUXBAUM, Adina**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **DESCLAUX, Mathieu**; c/o Regeneron Pharmaceuticals, Inc.,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: VIRAL PARTICLES RETARGETED TO NERVOUS SYSTEM TISSUES




FIG.1A

(57) Abstract: Provided herein are compositions and methods for retargeting viral particles, e.g., adeno-associated virus (AAV) particles, to p75^{NTR}-expressing cells using p75^{NTR}-targeting ligands. AAV adapted accordingly may be a viable gene therapy platform to target nervous system cells (e.g., dorsal root ganglia, trigeminal ganglia, etc.) for the treatment or prevention of pain, itch, or a neurological disease or disorder in a subject in need thereof.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*